Abstract:Prednisone (PRED) is a synthetic glucocorticoid (GC) widely used in immunemediated diseases for its immunosuppressive and anti-inflammatory properties. The effects of GC are achieved by genomic and nongenomic mechanisms. However, the nongenomic effects are largely unknown. Thus, we aimed to investigate how long-term prednisone therapy changes the composition of the gut microbiota and fecal metabolites in rats. Male Sprague-Dawley rats were randomly assigned to a control (CON) group and a PRED group, which received prednisone treatment daily for 6 weeks by gavage. The V3 to V4 regions of bacterial 16S rRNA genes were amplified and sequenced after the total bacterial DNA was extracted from fecal samples. The alpha and beta diversities were calculated. The compositional alteration of the gut microbiota at different taxonomic levels was analyzed using the Metastats method. Meanwhile, the fecal metabolites were quantitated in an ultra-performance liquid chromatography system. Similar microbial richness and diversity between the CON and PRED groups were indicated by the alpha diversity results. The gut microbial communities differed significantly between two groups. The relative abundances of the genera Eisenbergiella, Alistipes, and Clostridium XIVb decreased, whereas that of Anaerobacterium increased significantly in rats after the 6-week prednisone treatment. In total, 11 downregulated and 10 upregulated fecal metabolites were identified. Differential fecal metabolites were enriched in the pathways, including phenylalanine metabolism, butanoate metabolism, and propanoate metabolism. The lowered production of short-chain fatty acids was associated with the decreased relative abundance of the genera Alistipes and Clostridium XIVb and increased abundance of the genus Anaerobacterium. The composition of the gut microbiota and fecal metabolites was changed after long-term prednisone treatment. This may help us to understand the pharmacology of prednisone. IMPORTANCE Prednisone is widely used in chronic glomerular diseases, immunological disorders, and rheumatic diseases for its anti-inflammatory and immunosuppressive properties. It is a synthetic glucocorticoid (GC) that shows therapeutic effects after conversion to prednisolone by the liver. Prolonged GC therapy causes anti-inflammatory effects; it also results in a variety of adverse events, including obesity, hypertension, psychiatric symptoms, and dyslipidemia. The therapeutic effects and adverse events of GCs may be associated with changes in the gut microbiota, as the host might be affected by the metabolites generated by the altered gut microbes. Thus, we investigated how long-term prednisone therapy changed the composition of the gut microbiota and fecal metabolites in rats. This study may shed new light on the pharmacology of prednisone.

Tandem analysis of transcriptome and proteome changes after a single dose of corticosteroid: a systems approach to liver function in pharmacogenomics.

Highly Multiplexed and Reproducible Ion-Current-based Strategy for Large-Scale Quantitative Proteomics and the Application to Protein Expression Dynamics Induced by Methylprednisolone in 60 Rats.

Timing of glucocorticoid administration determines severity of lipid metabolism and behavioral effects in rats.

Physiologically Based Pharmacokinetic Modeling: The Reversible Metabolism and Tissue-Specific Partitioning of Methylprednisolone and Methylprednisone in Rats

Time-course cross-species transcriptomics reveals conserved hepatotoxicity pathways induced by repeated administration of cyclosporine A

Pleiotropic Signaling Pathways in Rapid, Nongenomic Action of Glucocorticoid

Selective amplification of glucocorticoid anti-inflammatory activity through synergistic multi-target action of a combination drug

The effect of tacrolimus-induced toxicity on metabolic profiling in target tissues of mice

Integrative Analysis of Gut Microbiota and Fecal Metabolites in Rats after Prednisone Treatment

Mass spectrometry and its evolving role in assessing tissue specific steroid metabolism

Effects of the glucocorticoid drug prednisone on urinary proteome and candidate biomarkers

Pharmacogene expression during progression of metabolic dysfunction-associated steatotic liver disease: Studies on mRNA and protein levels and their relevance to drug treatment

High-dose dexamethasone injection disordered metabolism and multiple protein kinases expression in the mouse kidney

Epigenetic Mechanisms Modulated by Glucocorticoids With a Focus on Cushing Syndrome

Metabonomic Study on the Biochemical Profiles of A Hydrocortisone-Induced Animal Model

Effects of Prednisolone on the Physiological Factors Regulating Cyclosporin A Blood Distribution in Renal Transplant Patients.

Corticosteroids for infectious critical illness: A multicenter target trial emulation stratified by predicted organ dysfunction trajectory

Long-term Prednisone Treatment Causes Fungal Microbiota Dysbiosis and Alters the Ecological Interaction Between Gut Mycobiome and Bacteriome in Rats

Biological effects of corticosteroids on pneumococcal pneumonia in Mice—translational significance

Corticosteroid receptor rebalancing alleviates critical illness-related corticosteroid insufficiency after traumatic brain injury by promoting paraventricular nuclear cell survival via Akt/CREB/BDNF signaling

Blood and tissue correlates of steroid non-response in checkpoint inhibition-induced immune-related adverse events